SCHEMBL4003312

SCHEMBL4003312

C[C@@H]1Cc2[nH]cnc2CN1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADRA1A P35348 6/20 0.39
ADRA1D P25100 1/20 0.36
PNMT P11086 2/20 0.33
ADRA2A P08913 2/20 0.33
ADRA2B P18089 2/20 0.33
ADRA2C P18825 2/20 0.33
HTR3A P46098 2/20 0.30
SLC6A4 P31645 1/20 0.30
OPRK1 P41145 1/20 0.30
HTR2B P41595 1/20 0.30
KCNH2 Q12809 1/20 0.30
HTR3E A5X5Y0 1/20 0.30
HTR3B O95264 1/20 0.30
HTR3D Q70Z44 1/20 0.30
HTR3C Q8WXA8 1/20 0.30
RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4004122 1.00 ADRA1A (0.39) ADRA1AADRA1DPNMTADRA2AADRA2B
SCHEMBL4003317 1.00 ADRA1A (0.39) ADRA1AADRA1DPNMTADRA2AADRA2B
SCHEMBL17133018 0.85 ADRA1A (0.36) ADRA1AADRA1DPNMTADRA2AADRA2B
SCHEMBL12082249 0.85 ADRA1A (0.36) ADRA1AADRA1DPNMTADRA2AADRA2B
SCHEMBL9582230 0.72 EGLN1 (0.46) ADRA1AADRA2AADRA2BADRA2CHTR3A
SCHEMBL3739922 0.72 EGLN1 (0.46) ADRA1AADRA2AADRA2BADRA2CHTR3A
SCHEMBL10082451 0.71 KDM4E (0.45) ADRA1AADRA1DADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL3804263 0.70 EGLN1 (0.44) ADRA1AADRA2AADRA2BADRA2CHTR3A
SCHEMBL4791862 0.70 KDM4E (0.38) ADRA1AADRA1DADRA2AADRA2BADRA2C
Hydrochloric Acid SCHEMBL3738082 0.70 EGLN1 (0.44) ADRA1AADRA2AADRA2BADRA2CHTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8258129-B2 4-heterocycloalkylpyri(mi)dines, process for the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-09-04 US disclosed
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-13 US disclosed
EP-2041132-A2 NEW COMPOUNDS Boehringer Ingelheim International GmbH (DE) 2009-04-01 EP disclosed
WO-2008003766-A2 4-HETER0CYCL0ALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203673-A1 4-HETEROCYCLOALKYLPYRI(MI)DINES, PROCESS FOR THE PREPARATION THEREOF AND THEIR USE AS MEDICAMENTS CCNI, MKI67, CCNA1 ADRA1A 224/4885ADRA1D 193/4885PNMT 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.